Overview

A Study in Patients With Trichotillomania

Status:
Completed

Trial end date:
2019-12-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 when dosed for 6 weeks versus placebo in adult patients with moderate to severe Trichotillomania.

Phase:

Phase 2

Details

Lead Sponsor:

Promentis Pharmaceuticals, Inc.